Related to Evotec Partners with Harvard and HHMI on Beta Cell Regeneration Approach to Diabetes

• Apeiron Teams Up with Evotec for R&D in Pain
  
• Zhejiang Jingxin to Develop Evotec’s Clinical-Stage Insomnia Candidate in China
  
• Evotec and Merck KGaA Sign Neurological Drug Discovery Deal
  
• MedImmune Nabs Evotec’s Beta Cell Regeneration Portfolio for €5M Up Front
  
• Evotec Expands Screening Library with Addition of 110,000 ChemBridge Compounds
  
• Oxford Nanopore Licenses Harvard’s Graphene Nanopore Technology for Nucleic Acid Sequencing
  
• Proteostasis Therapeutics Licenses Protein Clearance Targets and Compounds from Harvard
  
• Evotec and PsychoGenics Ally to Offer Integrated CNS Drug Discovery Solutions
  
• UCB and Harvard Establish Research Alliance to Develop Antibody Therapeutics
  
• Roche Pays Evotec $10M Up Front in Deal to Develop MAO-B Inhibitor for Alzheimer Disease
  
• Conba Licenses Evotec’s Anti-Inflammatory Candidate EVT 401 in China
  
• Evotec Inks €7.7M Compound Management Contract with EPA
  
• Evotec Becomes First European CRO to Offer Agilent’s RapidFire Screening Tool
  
• Wandering Tumor Cells May Seed Metastasis in Breast Cancer
  
• Evotec, Dana-Farber Partner on Cancer Epigenetics Drug Development
  
• Sequencing Study IDs Spontaneous Mutations in Congenital Heart Disease
  
• Evotec, Harvard, and Brigham & Women’s Partner on Kidney Diseases
  
• CureBeta Snags $8M Up Front for Beta-Cell Regeneration Candidates
  
• Hormone Holds Promise for Replacing Insulin Injections
  
• Evotec, Harvard Go on Antibacterial Drug Hunt